Profiling of Genetic Mutations among Adult Filipino Patients Diagnosed with Acute Myeloid Leukemia using Fluorescence In Situ Hybridization from 2014 to 2021
A Single-Institution Study
DOI:
https://doi.org/10.21141/PJP.2023.06Keywords:
acute myeloid leukemia, fluorescence in situ hybridization, cytogenetics, profiling, hematologyAbstract
Introduction. Among patients with Acute Myeloid Leukemia (AML), the karyotype at diagnosis is an important prognostic indicator for predicting outcomes. Several studies have been done to identify the most common cytogenetic abnormalities seen in patients in other countries, however, limited studies have been done in our setting.
Objective. The study aims to determine the most common abnormalities present among patients with AML referred for Fluorescence in situ Hybridization (FISH) at the National Kidney and Transplant Institute.
Methodology. The study included 131 adult patients with a mean age of 46. Fluorescence in situ Hybridization was used to identify the following cytogenetic abnormalities: t(8;21), 11q23 (MLL), 16q22 (CBFB-MYH11), t(15;17) (PML/RARA), t(9;22) (BCR/ABL), 7q31 deletion, and Monosomy 7.
Results. FISH was negative in 40% (n=53) of patients. 7q31 deletion is the most frequently identified cytogenetic abnormality among patients with a single abnormality (n=17, 13%) present and is the most frequently identified abnormality among patients with multiple abnormalities (n=26). 7q31 deletion is more frequently observed among patients between the ages 51 to 60 years old and among patients with AML with monocytic differentiation. 22% (n=29) of patients have multiple abnormalities, with the most common abnormalities to occur together are 7q31 deletion and t(8;21) (n=20, 15%). Patients with negative results and patients with multiple cytogenetic abnormalities are commonly seen within the 41 to 50 age group.
Conclusion. The current study provides a single-institution view of the cytogenetic abnormalities among adult Filipino patients with AML using FISH. Further investigation on the clinical history of these patients, with correlation with other methods, as well as epidemiologic studies are needed to better understand the similarities and differences seen from previously reported incidences.
Downloads
References
Elnaggar MG, Mosad E, Makboul A, Shafik EA. Cytogenetic profile of adult acute myeloid leukemia
in Egypt: a single-center experience. Mol Cytogenet. 2022;15(43):1–8. https://doi.org/10.1186/s13039-022-00621-1
Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2013 National Cancer Institute SEER Cancer Statistics Review 1975- 2018, National Cancer Institute. National Cancer
Institut. Bethesda, MD, https://seer.cancer.gov/archive/csr/1975_2018/, based on November 2020 SEER data submission, posted to the SEER web site, April 2021.
Meng CY, Noor PJ, Ismail A, Md Ahid MF, Zakaria Z. Cytogenetic profile of de novo acute myeloid leukemia patients in Malaysia. Int J Biomed Sci. 2013;9(1):26-32. https://pubmed.ncbi.nlm.nih.gov/23675286. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644412.
Mrózek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and
gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for
a prognostically prioritized molecular classification? Blood. 2007;109(2):431–48. https://pubmed.ncbi.nlm.nih.gov/16960150. Phttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1785102. https://doi.org/10.1182/blood-2006-06-001149.
Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute
myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and
usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100(1):59–66. https://pubmed.ncbi.nlm.nih.gov/12070009. https://doi.org/10.1182/blood.v100.1.59.
Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood. 2005;106(12):3740–6. https://pubmed.ncbi.nlm.nih.gov/16051734. https://doi.org/10.1182/blood-2005-05-2164.
WHO Classification of Tumours Editorial Board. Haematolymphoid tumours [Internet; beta version
ahead of print]. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2022 Nov 13].
(WHO classification of tumours series, 5th ed.; vol. 11). https://tumourclassification.iarc.who.int/chapters/63.
Mrózek K, Heinonen K, Bloomfield CD. Prognostic value of cytogenetic findings in adults with acute
myeloid leukemia. Int J Hematol. 2000;72(3):261–71. https://pubmed.ncbi.nlm.nih.gov/11185980.
Mrózek K, Bloomfield CD. Chromosome abnormalities in acute myeloid leukaemia and their clinical
importance. In: Chromosomal Translocations and Genome Rearrangements in Cancer; 2015.
Kim HJ, Cho HI, Kim EC, et al. A study on 289 consecutive Korean patients with acute leukaemias
revealed fluorescence in situ hybridization detects the MLL translocation without cytogenetic evidence
both initially and during follow-up. Br J Haematol. 2002;119(4):930-9. https://pubmed.ncbi.nlm.nih.gov/12472570. https://doi.org/10.1046/j.1365-2141.2002.03937.x.
Tallman MS, Wang ES, Altman JK, et al. Acute myeloid leukemia, version 3.2019. JNCCN J Natl Compr
Cancer Netw. 2019;17(6):721–49. https://pubmed.ncbi.nlm.nih.gov/31200351. https://doi.org/10.6004/jnccn.2019.0028.
Byun JM, Kim YJ, Yoon HJ, et al. Cytogenetic profiles of 2806 patients with acute myeloid leukemia—a
retrospective multicenter nationwide study. Ann Hematol. 2016;95(8):1223–32. https://pubmed.ncbi.nlm.nih.gov/27230620.
https://doi.org/10.1007/s00277-016-2691-1.
Liu H, Chang N bai, Pei L, et al. [The cytogenetic characteristics of 178 acute myeloid leukemia patients]. Zhonghua Nei Ke Za Zhi. 2011;50(8):683–6. https://pubmed.ncbi.nlm.nih.gov/22093563.
Shaikh MS, Ahmed ZA, Shaikh MU, et al. Distribution of chromosomal abnormalities commonly observed in adult acute myeloid leukemia in Pakistan as predictors of prognosis. Asian Pacific J Cancer Prev. 2018;19(7):1903–6. https://pubmed.ncbi.nlm.nih.gov/30049204. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165659. https://doi.org/10.22034/APJCP.2018.19.7.1903.
Bagchi B, Dolai TK, Dutta S, et al. Cytogenetic profile of acute leukemia: single centre study from
India (Abstract 115). In: 51st National Conference of Indian Society of Hematology November 18-21, 2010, Kolkata, India. Indian J Hematol Blood Transfus. 2010;26(4):129–81. https://doi.org/10.1007/s12288-010-0045-z.
Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325–36. https://pubmed.ncbi.nlm.nih.gov/12393746. https://doi.org/10.1182/blood-2002-03-0772.
Chen X, Wood BL, Cherian S. Immunophenotypic features of myeloid neoplasms associated with
chromosome 7 abnormalities. Cytometry B Clin Cytom. 2019;96(4):300–9. https://pubmed.ncbi.nlm.nih.gov/30806023. https://doi.org/10.1002/cyto.b.21775.
Woo K, Kim K, Kim K, et al. Deletions of chromosome arms 7p and 7q in adult acute myeloid leukemia: a marker chromosome confirmed by array comparative genomic hybridization. Cancer Genet Cytogenet. 2009;194(2):71–4. PMID: 19781438. https://doi.org/10.1016/j.cancergencyto.2009.04.017.
El-Menoufy MAM, Mourad ZI, Farahat NM. The prognostic impact of loss of chromosome 7 material
detected by fluorescence in situ hybridization (FISH) in myeloid malignancies. J Egypt Natl Canc Inst.
;30(4):133–8. PMID: 30472199. https://doi.org/10.1016/j.jnci.2018.11.001.
McNerney ME, Brown CD, Wang X, et al. CUX1 is a haploinsufficient tumor suppressor gene on
chromosome 7 frequently inactivated in acute myeloid leukemia. Blood. 2013;121(6):975-83. PMID:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567344. https://doi.org/10.1182/blood-2012-04-426965.
Gonzales PR, Mikhail FM. Diagnostic and prognostic utility of fluorescence in situ hybridization (FISH) analysis in acute myeloid leukemia. Curr Hematol Malig Rep. 2017;12(6):568–73. PMID: 29064023.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 PJP
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Philippine Journal of Pathology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on works made open access at http://philippinejournalofpathology.org
@philippinepathologyjournal